Konservativnaya terapiya stressovogo nederzhaniya mochi (s primeneniem duloksetina)

Cite item

Full Text


About the authors

N N Stenyaeva

I A Apolikhina


  1. Аполихина И.А., Кулаков В.И. Недержание мочи у женщин: клиника, диагностика, лечение. Поликлиническая гинекология (клинические лекции). Под ред. В.Н.Прилепской. М.: Медпресс-информ, 2004; с. 479-87.
  2. Abrams P, Cardozo L, Fall M et al. The standartisation of terminology in lower urinary tract function. Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21 (2): 167-78.
  3. Ashton AK, Jamerson BD, Weinstein WL, Wagoner C. Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey. Curr Ther Res 2005; 66: 96-106.
  4. Bo K, Kvarstein B, Nygaard I. Lower urinary tract symptoms and pelvic floor muscle exercise adherence after 15 years. Obstet Gynecol 2005; 105 (5): 999-1005.
  5. Bump RC, Voss S, Beardsworth A et al. Long-term efficacy of duloxetine in women with stress urinary incontinence. BJU International 2008; 102 (2): 214-8.
  6. Bymaster FP, Dreshfield Ahmed LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, hyman serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25: 871-80.
  7. Cardozo L, Drutz HP, Baygani SK, Bump RC. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynecol 2004; 104 (3): 511-9.
  8. Chalon S, Granier LA, Vandenhende F et al. Duloxetine: clinical evidence of serotoninergic and noradrenergic reuptake blockage. Clin Pharmacol Ther 2001; 69 (2): 18.
  9. Cheater FM, Castleden CM. Epidemiology and classification of urinary incontinence. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14 (2): 183-205.
  10. Delgado PL, Brannan SK, Mallinckrodt CH et al. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005; 66 (6): 686-92.
  11. Dmochowski RR, Miklos JR, Norton PA et al. Duloxetine versus placebo for the treatment of North American women. J Urol 2003; 170: 1259-63.
  12. Freeman RM. Initial management of stress urinary incontinence: pelvic floor muscle training and duloxetine. BJOG 2006; 113 (Suppl. 1): 10-6.
  13. Ghoniem GM, Schagen van Leeuwen J, Elser DM et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 2005; 173: 1647-53.
  14. Mihaylova B, Pitman R, Tincello D et al. Cost-Effectiveness of Duloxetine: The Stress Urinary Incontinence Treatment (SUIT) Study. Value in Health 2010; 13 (5): 565-72.
  15. Millard RJ, Moore K, Rencken R et al. Duloxetine versus placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int 2004; 93: 311-8.
  16. Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002; 187: 40-8.
  17. Pauls RN, Segal JL, Silva WA et al. Sexual function in patients presenting to an urogynecology practice. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17 (6): 576-80.
  18. Persson J, Wolner-Hanssen P, Rydhstroem H. Obstetric risk factors for stress urinary incontinence: a population study. Obstet Gynecol 2000; 96 (3): 440-5.
  19. Robinson D, Cardozo L. New drug treatments for urinary incontinence. Maturitas 2010; 65: 340-7.
  20. Sand PK, Goldberg RP, Dmochowski RR et al. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol 2006; 195: 1730-5.
  21. Schagen van Leeuwena JH, Lange RR, Jonasson AF et al. Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinence. Maturitas 60 2008; p. 138-47.
  22. Skinner MH, Kuan H, Skerjanec A et al. Effect of age on the pharmacokinetics of duloxetine in women. Br J Clin Pharmacol 2004; 57 (1): 54-61.
  23. Stach-Lempinen B, Hakala AL, Laippala P et al. Severe depression determines quality of life in urinary incontinent women. Neurourol Urodyn 2003; 22 (6): 563-8.
  24. Sung VW, West DS, Hernandez AL et al. Association between urinary incontinence and depressive symptoms in overweight and obese women. Am J Obstet Gynecol 2009; 200 (5): 557.e1-557.e5.
  25. Thor KB, Donatucci C. Central nervous system control of the lower urinary tract: new pharmacological approaches to stress urinary incontinence in women. J Urol 2004; 172: 27-33.
  26. Thu Ёroff JW, Abrams P, Andersson K et al. EAU Guidelines on Urinary Incontinence. J Eur Urol 2011; 59: 387-400.
  27. Viktrup L, Lose G. The risk of stress incontinence 5 years after first delivery. Am J Obstet Gynecol 2001; 85 (1): 82-7.
  28. Zorn BH, Montgomery H, Pieper K et al. Urinary incontinence and depression. J Urol 1999; 162 (1): 82-4.

Copyright (c) 2012 Stenyaeva N.N., Apolikhina I.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies